Merck & Co., Inc. (BVL:MRK)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 1.02T +16.5% |
| Revenue (ttm) | 218.71B +1.3% |
| Net Income | 61.41B +6.6% |
| EPS | 24.49 +8.0% |
| Shares Out | n/a |
| PE Ratio | 16.57 |
| Forward PE | 22.90 |
| Dividend | 11.53 (9.64%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | n/a |
| Average Volume | 52 |
| Open | n/a |
| Previous Close | 119.50 |
| Day's Range | n/a |
| 52-Week Range | 76.10 - 121.06 |
| Beta | n/a |
| RSI | 66.74 |
| Earnings Date | Apr 30, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Barclays names top 4 defensive stocks to weather global uncertainty
As Dow Jones slides into the “correction territory” and the benchmark S&P 500 index logs its fifth consecutive week of losses, investors are increasingly desperate for a port in the storm. According t...
Infinimmune, Merck enter into antibody discovery pact
Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck , that could be worth up to about $838 million in milestone payments, to discover and develop multiple antibodies for ...
Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics
ALAMEDA, Calif.--(BUSINESS WIRE)-- #AI--Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics.
Merck's drug reduced bad cholesterol by 64.6% in late-stage trial
Merck's oral drug reduced bad cholesterol by 64.6% in a late-stage trial, it said on Monday, as the company looks for its next blockbuster candidate.
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies.
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal
Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss f...
Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter.
Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year res...
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the...
Merck Marks 10 Years of SPARK™ Mobilizing Employee Volunteers to Help Inspire the Next Generation in STEM
Darmstadt, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- Employee volunteer program brings hands-on science learning to communities worldwide More than 600.000 students reached and nearly 200.000 employ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the l...
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company's cardio-pulmonary pipeline wil...
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv...
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AI-Powered Tempus Inks New Multi-Year Merck Deal
Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC.